Back to Search
Start Over
Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX)
Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX)
- Source :
- Journal of Clinical Oncology. 36:4107-4107
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- 4107Background: Chemotherapy is effective in mPDAC but new approaches are still needed to improve patients (pts) survival and quality of life. We have previously published successful results of a s...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Pancreatic ductal adenocarcinoma
business.industry
medicine.medical_treatment
Phases of clinical research
Gemcitabine
First line treatment
Irinotecan
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
FOLFIRI
business
medicine.drug
Nab-paclitaxel
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........92724253286ae1725d8be81c314eb5b5
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.4107